Tumor Cells‐Selective Bionic Nanodevice Exploiting Heparanase Combats Metastatic Breast Cancer
Source abstract
Abstract
Abstract The clinical application of the cytotoxic chemotherapeutic agents in the treatment of metastatic breast cancer is limited by their poor selectivity to cancer cells. In this work, a bionic nanodevice consisting of the docetaxel (DTX)‐heparan sulfate (HS) conjugate (HS‐DTX) micelle with a red blood cells membrane (RBC) coating on its surface, termed as rHS‐DTX, is first constructed. It is found that the cytotoxicity of DTX is concealed by HS in human mammary epithelial Michigan Cancer Foundation (MCF)‐10A cells but restored in human mammary cancer MCF‐7 cells because HS is hydrolyzed by heparanase (Hpa), which is overexpressed only in MCF‐7 but not MCF‐10A cells. The RBC coating enhances the cellular uptake of HS‐DTX and endows it with the long circulating ability in blood. In the MCF‐7 metastatic breast cancer mice model, rHS‐DTX exhibits 6.35‐fold higher intratumor DTX accumulation than the free DTX injection and achieves a tumor inhibiting rate of 98.2% and a lung metastasis suppression rate of 99.6%. No severe toxicity is observed in the major organs and blood of mice treated with rHS‐DTX. In summary, rHS‐DTX can provide a promising strategy for targeting therapy of metastatic breast cancer by improving the tumor‐suppressing efficacy of DTX.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Cancer Cells and Metastasis · Fibroblast Growth Factor Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Drug Research and Center of Pharmaceutics Shanghai Institute of Materia Medica Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China
School of Pharmacy University of Chinese Academy of Sciences Beijing 100049 China
Funding
National Natural Science Foundation of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences
References (25)
Show source-provided references
1. 10.3322/caac.2138710.3322/caac.21387 ↗
2. Gligorov J. · Nat. Rev. Clin. Oncol. · 2015 · 12 · 50810.1038/nrclinonc.2015.137 ↗
3. 10.1038/nrclinonc.2015.12310.1038/nrclinonc.2015.123 ↗
4. 10.1002/adfm.20160567910.1002/adfm.201605679 ↗
5. 10.1038/natrevmats.2016.7510.1038/natrevmats.2016.75 ↗
6. 10.1002/adfm.20170040310.1002/adfm.201700403 ↗
7. 10.1158/1078-0432.CCR-17-024210.1158/1078-0432.CCR-17-0242 ↗
8. Zhao B. B. · Exp. Hematol. · 2016 · 44 · 97510.1016/j.exphem.2016.06.249 ↗
9. 10.1016/j.matbio.2013.02.00610.1016/j.matbio.2013.02.006 ↗
10. 10.1002/smll.20160206610.1002/smll.201602066 ↗
11. 10.1038/nature1537310.1038/nature15373 ↗
12. 10.1002/adma.20160217310.1002/adma.201602173 ↗
13. 10.1002/adfm.20150478010.1002/adfm.201504780 ↗
14. 10.1021/acsnano.5b0104210.1021/acsnano.5b01042 ↗
15. 10.1002/adfm.20160338110.1002/adfm.201603381 ↗
16. 10.1007/s10549-014-3159-410.1007/s10549-014-3159-4 ↗
17. 10.1007/s12307-011-0082-710.1007/s12307-011-0082-7 ↗
18. 10.1016/j.jconrel.2010.02.02910.1016/j.jconrel.2010.02.029 ↗
19. 10.1021/acs.nanolett.7b0233010.1021/acs.nanolett.7b02330 ↗
20. 10.1002/adfm.20150128310.1002/adfm.201501283 ↗
21. 10.3892/mco.2017.128110.3892/mco.2017.1281 ↗
22. 10.1021/ar400300910.1021/ar4003009 ↗
23. 10.1038/ncb269010.1038/ncb2690 ↗
24. 10.1038/s41598-017-02591-610.1038/s41598-017-02591-6 ↗
25. 10.1093/annonc/mdv12910.1093/annonc/mdv129 ↗